Rockefeller Capital Management L.P. Raises Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Rockefeller Capital Management L.P. increased its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 81.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 585,497 shares of the medical equipment provider's stock after acquiring an additional 262,504 shares during the quarter. Rockefeller Capital Management L.P. owned about 1.27% of BioLife Solutions worth $14,661,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. 1620 Investment Advisors Inc. bought a new position in BioLife Solutions in the second quarter valued at about $35,000. Isthmus Partners LLC boosted its stake in BioLife Solutions by 34.4% during the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 42,265 shares during the last quarter. Quest Partners LLC bought a new position in BioLife Solutions during the 3rd quarter valued at $57,000. GAMMA Investing LLC boosted its stake in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after buying an additional 748 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in BioLife Solutions in the 2nd quarter valued at $122,000. Institutional investors own 93.24% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on BLFS. Craig Hallum upped their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. TD Cowen raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. HC Wainwright decreased their price objective on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, November 18th. Finally, Northland Securities upped their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.50.

BioLife Solutions Trading Down 1.7 %

Shares of NASDAQ BLFS traded down $0.46 during midday trading on Tuesday, hitting $26.81. 294,157 shares of the stock traded hands, compared to its average volume of 602,615. BioLife Solutions, Inc. has a one year low of $12.45 and a one year high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm has a 50-day moving average of $24.27 and a two-hundred day moving average of $23.28.

Insider Activity

In other news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares of the company's stock, valued at $2,883,097.76. This represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of the company's stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares of the company's stock, valued at $7,593,412.40. This represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,313 shares of company stock valued at $1,572,899 in the last quarter. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.